Arthropathy of Knee Joint Clinical Trial
Official title:
A Personalized Medicine Prehabilitation Intervention Delivered Using Wearable Mobile Devices to Improve Cognitive Function in Elective Joint Replacement Surgery
Verified date | September 2023 |
Source | University of Pennsylvania |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The mission is to develop novel interventions to improve cognitive function, and thereby reducing delirium in hospitalized patients to improve perioperative outcomes. Delirium affects up to 42% of hospitalized patients and disproportionately increases morbidity and mortality in older adults, especially after surgical procedures. Current approaches prevent only 30-40% of delirium cases. The goal is to use prehabilitation (an individualized exercise regimen performed in the 2-4 weeks prior to admission) to improve peri-operative cognitive status, mobility and recovery. Based on preliminary data, the investigators propose to deeply phenotype patients, meaning to study the patient, the disease and surgery in a very detailed fashion, with elective knee or hip replacement surgery and use a personalized prehabilitation intervention compared to standard pre-operative care. To facilitate data collection over the course of the study, the investigators use wearable devices and mobile phone applications.
Status | Suspended |
Enrollment | 28 |
Est. completion date | December 31, 2026 |
Est. primary completion date | December 31, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 55 Years and older |
Eligibility | Inclusion Criteria: - Adults scheduled for elective arthroplasty; - =55 years of age; - Capable of giving informed consent; - Willing to comply either to undergo prehabilitation (cases) or standard preoperative care (control); - Own a smartphone. Exclusion Criteria: - Patients with bilateral or revision surgeries; - Diagnosis of pre-existing dementia; - Test result of <20 in the MoCA indicating moderate to severe dementia; - Diagnosis of acute stroke; - Diagnosis of neurologic injury; - Current alcohol (more than 2 drinks a day with last drink within the past 3 days) or substance abuse (positive urine dip test for illicit drugs) history at risk of postoperative withdrawal; - Active diagnosis of alcohol or substance abuse; - Recent travel across more than two (2) time zones (within the past month); - Planned travel across more than two (2) time zones during the planned study activities; - Subjects, who have received an experimental drug, used an experimental medical device within 30 days prior to screening, or who gave a blood donation of = one pint within 8 weeks prior to screening; - Subjects without access to WiFi in their or close to home or at work. |
Country | Name | City | State |
---|---|---|---|
United States | University of Pennsylvania School of Medicine | Philadelphia | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
University of Pennsylvania |
United States,
Skarke C, Lahens NF, Rhoades SD, Campbell A, Bittinger K, Bailey A, Hoffmann C, Olson RS, Chen L, Yang G, Price TS, Moore JH, Bushman FD, Greene CS, Grant GR, Weljie AM, FitzGerald GA. A Pilot Characterization of the Human Chronobiome. Sci Rep. 2017 Dec 7;7(1):17141. doi: 10.1038/s41598-017-17362-6. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from baseline, pre-prehabilitation cognitive function at 30±2 days post-operative | Difference in cognitive function as assessed by the CogState Brief Battery for the condition 'baseline, pre-prehabilitation' versus 30±2 days post-operative between Intervention vs. Control | 30±2 days post-operative | |
Secondary | Change from baseline, pre-prehabilitation physical activity [vector magnitude] at 30±2 days post-operative | Difference in physical activity for the condition 'baseline, pre-prehabilitation' versus 30±2 days post-operative between Intervention vs. Control | 30±2 days post-operative | |
Secondary | Change from baseline, pre-prehabilitation step count [number] at 30±2 days post-operative | Difference in step count for the condition 'baseline, pre-prehabilitation' versus 30±2 days post-operative between Intervention vs. Control | 30±2 days post-operative | |
Secondary | Change from baseline, pre-prehabilitation sleep duration [hours] at 30±2 days post-operative Difference in sleep parameters | Difference in sleep duration for the condition 'baseline, pre-prehabilitation' versus 30±2 days post-operative between Intervention vs. Control | 30±2 days post-operative | |
Secondary | Change from baseline, pre-prehabilitation circadian phase [hours] of activity | Difference in circadian phase for the condition 'baseline, pre-prehabilitation' versus 30±2 days post-operative between Intervention vs. Control | 30±2 days post-operative | |
Secondary | Change from baseline, pre-prehabilitation circadian amplitude [difference between the maximum and minimum observed values] of activity | Difference in circadian phase for the condition 'baseline, pre-prehabilitation' versus 30±2 days post-operative between Intervention vs. Control | 30±2 days post-operative | |
Secondary | Compliance | Compliance to the four-week prehabilitation paradigm assessed as the delta between the first and fourth (last) week of physical activity in the intervention group | 2 months | |
Secondary | Difference in incidence of delirium | Difference in incidence of delirium between Intervention vs. Control assessed from patient charts at 'post-operative day 30±2' | 30±2 days post-operative | |
Secondary | Difference in concentrations of Interleukin-6 (IL-6) [pg/mL] | Difference in concentrations between Intervention vs. Control | 30±2 days post-operative | |
Secondary | Difference in concentrations of S100ß [ng/mL] | Difference in concentrations between Intervention vs. Control | 30±2 days post-operative | |
Secondary | Difference in hospital length of stay | Difference in hospital length of stay [days] for Intervention vs. Control | 30±2 days post-operative |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03506347 -
Regional Prophylactic Vancomycin With Restricted Tourniquet Time in Primary Total Knee Replacement
|
Phase 2/Phase 3 | |
Recruiting |
NCT01198340 -
Evaluation of Optimal Dose of Local Anesthetics for Patient Controlled Continuous Femoral Nerve Block
|
N/A | |
Completed |
NCT03364088 -
Outcome After Total Knee Arthroplasty Under General or Spinal Anesthesia
|
N/A | |
Completed |
NCT03647709 -
Opioid-free Accelerated Recovery Total Knee Arthroplasty
|
||
Recruiting |
NCT03339323 -
The Effect of Exercise Training on Muscle Mass in Patients With Total Knee Arthroplasty
|
N/A | |
Completed |
NCT03668756 -
Comparison of Computer-Assisted Navigation and Conventional Instrumentation for Bilateral Total Knee Arthroplasty
|
||
Completed |
NCT01548664 -
The Utilization of Nintendo Wii™ in Outpatient Rehabilitation Following Total Knee Replacement
|
Phase 2 | |
Completed |
NCT01309035 -
Total Knee Arthroplasty - Accelerated Recovery Without Tourniquet
|
N/A | |
Completed |
NCT01364194 -
Local Infiltration With Bupivacaine to Increase Quality of Post-operative Pain Control in Total Knee Replacement
|
Phase 4 | |
Recruiting |
NCT05504577 -
Kaolin-based Hemostatic Gauze in Total Knee Arthroplasty
|
Phase 4 | |
Completed |
NCT01907178 -
Postoperative Pain Management in Hospital and Following Discharge From Hospital.
|
N/A | |
Completed |
NCT03044028 -
Neuromuscular Electrical Stimulation (NMES) for Improving Outcomes Following Total Knee Arthroplasty (TKA)
|
N/A | |
Completed |
NCT00967161 -
Motion Analysis of EMP Knee Versus Posterior Stabilized Knee Arthroplasty for Osteoarthritis
|
N/A | |
Completed |
NCT01333189 -
Improving Function After Knee Arthroplasty With Weight-Bearing Biofeedback
|
N/A | |
Completed |
NCT06124651 -
Comparison of Cruciate Retaining and Posterior Stabilized Total Knee Arthroplasty
|
N/A | |
Recruiting |
NCT04814082 -
Prospective Functional, Gait, and Outcome Comparison Study of Medial Pivot Versus Single Radius Design for Total Knee Arthroplasty
|
N/A | |
Completed |
NCT05266027 -
Naldebain for Pain Management After Knee Arthroplasty
|
Phase 4 |